Office for Infection Control, Asan Medical Center, Seoul, South Korea; Department of Infectious Diseases, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:
Published: May 2017
AI Article Synopsis
Article Abstract
Of 7,772 laboratory-confirmed cases of respiratory viral infection among hospitalized patients, 22.8% were categorized as having hospital-acquired infection. The overall incidence of hospital-acquired respiratory viral infection was 3.9 (95% confidence interval, 3.7-4.1) cases per 1,000 admitted patients. Rhinovirus was the most common virus (30.3%), followed by influenza virus (17.6%) and parainfluenza virus (15.6%).
Fungal infections related to biofilm formation on medical devices, such as endotracheal tubes (ETTs), pose significant health risks, especially during intubation procedures where fungi like Candida spp. can migrate into the lower respiratory tract. This study explores the use of Photodynamic Therapy (PDT) to prevent fungal cell migration from ETT surfaces to lungs, focusing on the role of curcumin as a photosensitizer.
Department of Respiratory Medicine, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, 518112, China.
Background: Adolescent pulmonary tuberculosis (TB) is considered inadequately recognized and underreported at high altitudes. This study aimed to investigate the clinical features of adolescent pulmonary TB patients at high altitudes in China.
Method: A retrospective analysis was performed at Linzhi People's Hospital.
Objectives: To identify the health and economic costs of hospital-acquired complications (HACs) in children who require PICU admission.
Design: Propensity score matched cohort study analyzing routinely collected medical and costing data collected by the health service over 6 years (2015-2020).
Setting: Tertiary referral PICU in Queensland, Australia.
Objectives: Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).
Methods: In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days.
Klebsiella pneumoniae is a major pathogen associated with hospital-acquired infections, particularly those involving multidrug-resistant strains. Carbapenem resistance, often driven by carbapenemases such as KPC, VIM, OXA-48, and NDM, poses a significant challenge in clinical settings. This study reports on K.
